DXR DAXOR CORP Insider Trading

CEO Feldschuh buys 1,000 DXR shares at $9.07; stock down 35.9% from 52-week high, company unprofitable

CEO Michael Richard Feldschuh purchased 1,000 shares at $9.07 on 2026-04-08, increasing his holdings to 213.7K shares. The purchase occurs amid substantial recent weakness: the stock is -35.9% from its 52-week high and down 16.9% over the past 30 days. Notably, his prior trades at DXR show a strong timing pattern—4 of 5 prior buys achieved positive 90-day returns, with the most recent two purchases (on 2025-04-04 and 2025-03-10) followed by +24.6% and +20.4% gains respectively. However, the company's fundamentals remain challenged: DAXOR is unprofitable (net income of $-4.2M in the latest quarter), revenues have contracted 8.4% year-over-year, and the market cap sits at only $39.7M. This buy occurs in a financially distressed context, though the insider's historical execution at this ticker suggests disciplined entry timing.

CFO Michel Robert J buys 1,000 DXR shares at $9.90; stock down 34.4% YTD, company unprofitable with -8.4% revenue decline

Michel Robert J, Chief Financial Officer of DAXOR CORP, purchased 1,000 shares at $9.90 on 2026-03-31, raising his holdings to 21,050 shares. The purchase occurs amid significant headwinds: the stock trades at $9.67 (down 34.4% from 52-week high of $14.75 and down 18.5% over 30 days), the company reported a net loss of $-4.2M in its latest quarter with annual revenue declining 8.4% year-over-year, and DAXOR has a market cap of only $40.6M with profitability challenges. At the same-ticker level, this executive's prior DXR purchases show mixed timing—3 of 5 prior buys were well-timed at the 90-day mark, but his most recent DXR purchase (2025-12-09) returned +10.4% at 30 days yet -9.6% at 90 days, suggesting volatility in outcomes. The current transaction occurs in a deteriorating fundamental environment with the stock near multi-month lows, warranting investigation into whether this reflects conviction despite headwinds or a response to valuation mechanics.

CMO John Jefferies buys 5,941 shares for $0.00 at Daxor; holdings rise to 23,557 shares (+33.7%) during -26.0% 90-day decline

Chief Medical Officer John Jefferies executed 2 separate purchases totaling 5,941 shares for $0.00 on 2026-03-20, increasing his stake by 33.7% to 23,557 shares. The zero transaction cost suggests these shares were acquired through equity compensation (vesting, grant, or exercise), not discretionary open-market buying. This acquisition occurred while Daxor's stock has declined 26.0% over 90 days and trades 30.6% below its 52-week high of $14.75, currently at $10.23. The company remains unprofitable with a net loss of $-4,183,669.00 in its latest full fiscal year and posted declining annual revenue growth of -8.4%, making the timing context—though forced by non-volitional equity compensation—relevant to assessing insider confidence given the company's financial deterioration.

CFO Michel Robert J buys 3,000 DXR shares, expanding stake by 17.6% to 20,050 shares

Michel Robert J, Chief Financial Officer of DAXOR CORP, purchased 3,000 shares on 2025-12-09, increasing his holdings from 17,050 to 20,050 shares—a 17.6% increase in his position. His prior trades at DXR show a strong 90-day timing pattern: 4 of 5 prior buys were followed by positive 90-day returns (+15.6%, +7.6%, -0.1%, +1.8%, +3.9%), suggesting the CFO has historically entered near favorable turning points. However, the current fundamental backdrop is challenging—the company reported a net loss of $4,183,669.00 in its latest quarter and annual revenue declined 8.4% year-over-year, with the company unprofitable for its full fiscal year. The stock is currently 11.9% below its 52-week high, and the CFO's purchase occurs in this weak period, presenting a test of whether his historical accuracy at this ticker extends to current market conditions.

CSO Jonathan Feldschuh buys 18,000 DXR shares, raising stake to 53,908; stock near 52-week lows amid unprofitable operations and -8.4% annual revenue decline.

Chief Scientific Officer Jonathan Feldschuh purchased 18,000 shares of Daxor Corp on 2025-12-09 at a $0.00 reported price, increasing his holdings by 50.1% to 53,908 shares post-transaction. The transaction occurs with DXR trading at $12.33, down 11.9% from its 52-week high of $14.00 and showing negative near-term momentum (-3.7% over 30 days). Fundamentally, the company faces significant headwinds: annual revenue declined 8.4% year-over-year, the latest quarterly revenue stands at $340,907.00, and net income was negative at -$4,183,669.00 over the most recent full fiscal year. Notably, Feldschuh's prior buy at this ticker on 2024-12-06 showed poor timing, with the stock declining 12.6% over both the 30-day and 90-day windows post-purchase—a pattern that recurred with the current acquisition entering a period of market weakness.

CMO John Jefferies purchases 2,344 shares of DAXOR (DXR); holdings rise 15.3% to 17.6K shares.

Jefferies John, Chief Medical Officer, purchased 2,344 shares on 2025-11-12, increasing his holdings by 15.3% to 17,616 shares total. The transaction occurred when the stock trades at $13.00, down 7.1% from its 52-week high of $14.00 but up 22.6% over the past 90 days. This purchase occurs against a backdrop of material operational headwinds: the company reported net income of $-4,183,669.00 for the latest full fiscal year, annual revenue declined 8.4% year-over-year, and most recent quarter revenue was only $340,907.00 on a $54.6M market cap. The timing of the buy (after a 22.6% three-month rally but below recent peaks) and the absolute increase in position size warrant examination of whether this reflects opportunistic accumulation or a scheduled plan, particularly given the company's sustained unprofitability and shrinking revenues.

CEO Michael Richard Feldschuh purchases 2,063 shares at $7.89; stock down 25.0% from 52-week high.

CEO Michael Richard Feldschuh purchased 2,063 shares on 2025-04-04 at $7.89, bringing holdings to 212,694 shares. The purchase occurs as the stock trades at $7.45, down 25.0% from its 52-week high of $9.94 and down 6.9% over the preceding 30 days. At Daxor, Feldschuh's timing pattern shows 3 of 4 prior DXR buys were well-timed at the 90-day mark, with measured outcomes ranging from -12.6% to +23.1%—mixed results with notable downside from the December 2024 purchase. Fundamentally, the company reported negative net income of $-4.2M in its latest quarter, annual revenue decline of -8.4%, and operates at a depressed market cap of $31.3M. The CEO's cross-ticker track record shows an average 90-day return of +3.9% across 8 prior buys elsewhere, but this purchase occurs within a context of operational losses and sustained stock weakness at this specific ticker.

CEO Feldschuh purchased 1,000 DXR shares at $8.13; stock -18.5% from 52-week high on $34.0M market cap, unprofitable fundamentals.

Michael Richard Feldschuh, Chief Executive Officer of Daxor Corp, purchased 1,000 shares at $8.13 on 2024-03-26, increasing his holdings to 210,631 shares. The transaction occurred while the stock trades at $8.10, currently -18.5% from its 52-week high of $9.94, and the company faces structural headwinds: revenue declined 8.4% year-over-year, with latest quarterly revenue of $340.9K and a full-year net loss of $-4.2M. His same-ticker history at DXR shows mixed outcomes (3 of 4 prior measurable 90-day returns were positive, most recently +8.3% following a March 2024 buy), though his cross-ticker track record across all holdings demonstrates modest success with a 66.67% 90-day win rate and +2.0% average 90-day return. The small position size (+1,000 shares, +0.5% of holdings) amid the company's unprofitable operating environment and recent stock weakness limits the signal strength of this transaction.

CEO Michael Richard Feldschuh buys 647 DXR shares at $8.15; 3 of 4 prior buys at this ticker were well-timed 90-day outcomes.

Feldschuh purchased 647 shares of Daxor at $8.15 on 2024-03-19, increasing his holdings by 0.3% to 209.6K shares. His prior open-market trading history across all tickers shows 7 buys with a 66.67% 90-day win rate, and at DXR specifically, 3 of his 4 measurable prior purchases posted positive 90-day returns, suggesting a pattern of reasonably-timed entry points at this company. However, the company's fundamentals present a headwind: it reported negative net income of $-4.2M, annual revenue contracted 8.4% year-over-year, and quarterly revenue of $340.9K remains modest relative to a $35.2M market cap. The most recent comparable buy at DXR (2024-12-06) yielded a -12.6% 90-day return, breaking the prior pattern and underscoring execution risk in a structurally weak operating environment.

CEO Michael Feldschuh purchases 3,360 DXR shares at $7.68; stock down 21.6% from 52-week high amid unprofitability

CEO Michael Feldschuh bought 3,360 shares at $7.68, increasing his holdings to 210.9K shares (+1.6%), at a time when DAXOR has declined 21.6% from its 52-week high of $9.94 and faces fundamental headwinds: annual revenue fell 8.4% year-over-year, and the company posted a $-4.2M net loss on $340.9K quarterly revenue. His cross-ticker track record shows a 71.43% 90-day win rate with +3.9% average 90-day return across 7 prior buys, but at this specific ticker (DXR), his timing has been mixed—while 4 of 5 prior trades showed positive 90-day returns, his most recent buy on 2024-12-06 declined 12.6% over 90 days. The current trade coincides with a 30-day rally of +4.4%, but comes in the context of ongoing operational losses and structural revenue contraction, making this purchase noteworthy for potential scrutiny of whether the CEO's commitment aligns with market skepticism.